219 related articles for article (PubMed ID: 18280641)
1. Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment.
Sigala S; Bodei S; Missale C; Zani D; Simeone C; Cunico SC; Spano PF
Mol Cell Endocrinol; 2008 Mar; 284(1-2):11-20. PubMed ID: 18280641
[TBL] [Abstract][Full Text] [Related]
2. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines.
Sigala S; Faraoni I; Botticini D; Paez-Pereda M; Missale C; Bonmassar E; Spano P
Clin Cancer Res; 1999 May; 5(5):1211-8. PubMed ID: 10353759
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
[TBL] [Abstract][Full Text] [Related]
4. A novel function of differentiation revealed by cDNA microarray profiling of p75NTR-regulated gene expression.
Nalbandian A; Pang AL; Rennert OM; Chan WY; Ravindranath N; Djakiew D
Differentiation; 2005 Oct; 73(8):385-96. PubMed ID: 16316409
[TBL] [Abstract][Full Text] [Related]
5. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
6. Nerve growth factor signaling in prostate health and disease.
Arrighi N; Bodei S; Zani D; Simeone C; Cunico SC; Missale C; Spano P; Sigala S
Growth Factors; 2010 Jun; 28(3):191-201. PubMed ID: 20166899
[TBL] [Abstract][Full Text] [Related]
7. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
8. Differential metastasis-associated gene analysis of prostate carcinoma cells derived from primary tumor and spontaneous lymphatic metastasis in nude mice with orthotopic implantation of PC-3M cells.
Chu JH; Sun ZY; Meng XL; Wu JH; He GL; Liu GM; Jiang XR
Cancer Lett; 2006 Feb; 233(1):79-88. PubMed ID: 15885894
[TBL] [Abstract][Full Text] [Related]
9. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes.
Yaqinuddin A; Abbas F; Naqvi SZ; Bashir MU; Qazi R; Qureshi SA
Biosci Rep; 2008 Dec; 28(6):319-26. PubMed ID: 18666890
[TBL] [Abstract][Full Text] [Related]
10. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
[TBL] [Abstract][Full Text] [Related]
11. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.
Kikugawa T; Kinugasa Y; Shiraishi K; Nanba D; Nakashiro K; Tanji N; Yokoyama M; Higashiyama S
Prostate; 2006 Jul; 66(10):1092-9. PubMed ID: 16637071
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
13. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells.
Asirvatham AJ; Schmidt MA; Chaudhary J
Prostate; 2006 Jun; 66(9):921-35. PubMed ID: 16541417
[TBL] [Abstract][Full Text] [Related]
14. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
[TBL] [Abstract][Full Text] [Related]
15. cDNA microarray analysis of pigment epithelium-derived factor-regulated gene expression profile in prostate carcinoma cells.
Liu W; Wu Z; Guan M; Lu Y
Int J Urol; 2009 Mar; 16(3):323-8. PubMed ID: 19207613
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
17. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
18. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.
Reyes I; Tiwari R; Geliebter J; Reyes N
Biomedica; 2007 Jun; 27(2):190-203. PubMed ID: 17713630
[TBL] [Abstract][Full Text] [Related]
19. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
20. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
Vaday GG; Peehl DM; Kadam PA; Lawrence DM
Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
